Qiagen (NYSE:QGEN) Shares Climb 7.7% – What’s Next?

Qiagen N.V. (NYSE:QGEN)’s stock price was up 7.7% on Friday. The company traded as high as $45.00 and last traded at $45.2920. Approximately 1,586,694 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 2,469,240 shares. The stock had previously closed at $42.04.

Analyst Ratings Changes

Several research analysts recently commented on QGEN shares. Jefferies Financial Group reiterated a “buy” rating and set a $48.00 price objective on shares of Qiagen in a research note on Thursday, August 6th. Weiss Ratings raised shares of Qiagen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, September 11th. JPMorgan Chase & Co. increased their price objective on Qiagen from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, August 7th. TD Cowen reissued a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Finally, Morgan Stanley restated an “overweight” rating on shares of Qiagen in a research note on Friday, September 11th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $43.51.

Qiagen Stock Up 6.9%

The stock has a market capitalization of $9.26 billion, a PE ratio of 23.01, a price-to-earnings-growth ratio of 4.36 and a beta of 0.61. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The business’s fifty day moving average price is $43.03 and its two-hundred day moving average price is $39.93.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The business had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. On average, equities research analysts forecast that Qiagen N.V. will post 2.43 EPS for the current fiscal year.

Institutional Trading of Qiagen

Institutional investors and hedge funds have recently bought and sold shares of the business. Manchester Capital Management LLC purchased a new position in shares of Qiagen during the fourth quarter worth $42,000. Hilltop National Bank purchased a new stake in Qiagen in the second quarter valued at $50,000. Integrated Wealth Concepts LLC acquired a new stake in Qiagen during the 2nd quarter worth about $59,000. Allworth Financial LP grew its position in Qiagen by 20.8% during the 2nd quarter. Allworth Financial LP now owns 1,841 shares of the company’s stock worth $72,000 after purchasing an additional 317 shares during the period. Finally, denkapparat Operations GmbH purchased a new position in shares of Qiagen during the 2nd quarter valued at about $105,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Company Profile

QIAGEN N.V. (NYSE:QGEN) is a global provider of sample technologies, molecular testing solutions and bioinformatics products. The company develops tools that help researchers and healthcare professionals isolate, analyze and interpret biological materials, including DNA, RNA and proteins.

Its portfolio includes laboratory kits and instruments for sample preparation, polymerase chain reaction (PCR), next-generation sequencing, genotyping and molecular diagnostics. QIAGEN also provides digital and bioinformatics solutions used to manage and analyze biological data.